Lexeo Therapeutics, Inc. Common Stock
- Open
- 4.82
- Day high
- 4.84
- Day low
- 4.63
- Prev close
- 4.86
- Volume
- 472K
- Mkt cap
- $391M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.7
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$300K over the last 3 months (0 open-market buys, 7 sales)
- 🏛Institutions reducing (13F)
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a Healthcare company listed on NASDAQ. The stock is down 3% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 7 sales (SEC Form 4).
Lexeo Therapeutics, Inc. Common Stock (LXEO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
LXEO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 12, 2026 | $-0.29 | $-0.30 | -5.2% | — | — |
| May 11, 2026 | $-0.29 | $-0.25 | +13.8% | — | — |
| Mar 30, 2026 | $-0.32 | $-0.27 | +15.6% | — | — |
| Nov 5, 2025 | $-0.48 | $-0.33 | +31.2% | — | — |
| Aug 14, 2025 | $-0.64 | $-0.60 | +6.3% | — | — |
| Mar 24, 2025 | $-0.87 | $-0.78 | +10.3% | — | — |
| Nov 13, 2024 | $-0.65 | $-0.89 | -36.9% | — | — |
| May 9, 2024 | $-0.76 | $-0.77 | -1.3% | — | — |
| Mar 11, 2024 | $-0.73 | $-0.85 | -16.4% | — | — |
LXEO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 1,304 | $4.96 |
| Aug 19, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Sell | 4,117 | $4.91 |
| Aug 19, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 3,345 | $4.95 |
| Jul 1, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Sell | 4,641 | $4.49 |
| Jul 1, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Grant | 12,000 | — |
| Jul 1, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 25,947 | $4.48 |
| Jul 1, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Grant | 12,060 | — |
| Jul 1, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 4,666 | $4.48 |
| Jul 1, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Grant | 55,000 | — |
| Jul 1, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Sell | 22,306 | $4.42 |
| Jul 1, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 67,000 | — |
| Jun 29, 2026 | DIAZ REINALDO Mdirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | Tanguler Tolgadirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | Van Hauwermeiren Timothydirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | CHOLMONDELEY PAULA Hdirector | Grant | 35,000 | $4.70 |
Source: LXEO SEC Form 4 filings, latest Aug 19, 2026. For informational purposes only — not investment advice.
See the full LXEO insider & 13F page →Lexeo Therapeutics, Inc. Common Stock company profile
Overview
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company founded in 2017 and headquartered in New York, New York. The company went public in November 2023 and focuses on developing gene therapies for both hereditary and acquired diseases. Lexeo operates in the biotechnology sector, specifically targeting genetic disorders through advanced gene therapy approaches using adeno-associated virus (AAV) vectors.
Business
Lexeo Therapeutics operates in the gene therapy segment of the biotechnology industry, developing treatments for genetic diseases by introducing functional genes into patients' cells to correct defective or missing genes. Gene therapy represents a cutting-edge approach to treating diseases at their genetic root cause, rather than merely managing symptoms. The company's pipeline consists of multiple gene therapy candidates targeting two primary disease areas. The cardiovascular portfolio includes LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy, and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 mutations. These conditions are rare genetic disorders that affect heart muscle function and can lead to heart failure or sudden cardiac death. The neurological portfolio focuses on brain-related genetic disorders, including LX1001, LX1020, and LX1021 for APOE4 homozygous patients (associated with increased Alzheimer's disease risk), and LX1004 for CLN2 Batten disease, a rare neurodegenerative disorder affecting children. All of Lexeo's gene therapy candidates utilize AAVrh10 vectors, which are engineered viruses that can deliver therapeutic genes to specific tissues while minimizing immune responses. The company currently generates no revenue from product sales, as all candidates remain in preclinical or early clinical development stages, representing a typical profile for an early-stage biotechnology company.
Revenue model
Lexeo Therapeutics currently operates under a traditional biotechnology development model with no revenue generation, as evidenced by zero revenue across all reported periods. The company is entirely dependent on external funding through equity raises and potential future partnerships to finance its operations and clinical trials. The company's future revenue model will likely involve multiple streams once products reach commercialization. Product sales would represent the primary revenue source, with gene therapies typically commanding premium pricing due to their one-time treatment nature and targeting of rare diseases with limited treatment options. Licensing agreements with larger pharmaceutical companies could provide upfront payments, milestone payments, and royalties. Partnership deals may also generate development funding and risk-sharing arrangements. Several factors could significantly impact Lexeo's future margins and commercial success. Regulatory approval timelines and success rates will determine when and if products reach market, while manufacturing costs for gene therapies remain substantial due to complex production requirements. Competition from other gene therapy companies and traditional pharmaceutical approaches could affect pricing power. Reimbursement policies from healthcare systems will be critical, as gene therapies often require health insurers to approve expensive one-time treatments. Clinical trial outcomes represent the most immediate risk, as negative results could eliminate entire product candidates and require significant additional investment to advance alternative approaches.
Competitive moat
Lexeo Therapeutics operates in a highly competitive and rapidly evolving gene therapy landscape with limited sustainable competitive advantages at its current stage of development. The company's primary potential moat lies in its intellectual property portfolio and specialized expertise in AAVrh10 vector technology, though these advantages are not yet proven in the market. The company's focus on rare genetic diseases provides some protection from competition, as these markets are typically too small to attract multiple competitors for each indication. However, this also limits the ultimate revenue potential. Lexeo's early-mover advantage in specific indications like Friedreich's ataxia cardiomyopathy could provide temporary competitive positioning, but gene therapy is an area of intense research and development activity among both biotechnology companies and large pharmaceutical corporations. The company faces significant competitive threats from established gene therapy companies with greater resources and more advanced clinical programs, traditional pharmaceutical approaches that may prove more effective or cost-efficient, and newer therapeutic modalities such as gene editing technologies. The regulatory pathway for gene therapies remains complex and expensive, creating barriers to entry that work both for and against Lexeo. While these barriers protect against smaller competitors, they also make it difficult for Lexeo to compete against well-funded rivals. Overall, Lexeo's moat is relatively weak at this stage, with the company's future success heavily dependent on clinical trial outcomes and its ability to execute on development programs faster and more effectively than competitors targeting similar indications.
Risks & safety
Lexeo presents significant financial risks typical of early-stage biotechnology companies, with limited margin of safety for investors. • Cash burn and solvency: The company burned $81.6 million in free cash flow during 2024, with quarterly burn rates of approximately $20-28 million. With $35 million in cash and short-term investments as of Q4 2024, the company has roughly 4-5 quarters of runway at current burn rates. • Debt levels: Minimal debt burden with debt-to-equity ratio of 0.08, indicating low financial leverage risk. • Liquidity position: Strong current ratio of 5.5 and quick ratio of 5.5, indicating good short-term liquidity management. • Valuation metrics: Trading at 1.8x book value with negative earnings making traditional valuation metrics less meaningful. Enterprise value to EBITDA of -1.9x reflects the pre-revenue nature of the business. • Other considerations: No revenue generation creates complete dependence on capital markets for funding. Clinical trial failures could eliminate significant asset value overnight. The company will likely need additional equity raises within the next 12-18 months, potentially causing dilution for existing shareholders.
Recent development
Based on the available financial data, Lexeo Therapeutics has been primarily focused on advancing its gene therapy pipeline through preclinical and early clinical development stages. The company has maintained a consistent research and development focus, as evidenced by substantial quarterly losses ranging from $21-33 million, reflecting ongoing investment in clinical trials and manufacturing capabilities. The company's cash position declined from $157 million in Q3 2024 to $35 million by Q4 2024, suggesting either significant clinical trial expenditures or potential milestone payments to development partners. This cash burn acceleration indicates the company is likely advancing multiple programs simultaneously or investing in manufacturing capabilities for upcoming clinical trials. Since going public in November 2023, Lexeo has been building its clinical infrastructure and regulatory capabilities to support its dual focus on cardiovascular and neurological gene therapies. The company's consistent zero revenue profile indicates it remains focused on development rather than seeking early partnership deals, suggesting management believes in the potential value of maintaining full ownership of its programs through key clinical milestones. The increasing operational cash burn from $54.6 million in 2022 to $81.2 million in 2024 reflects the natural progression of clinical programs into more expensive later-stage trials, though specific program updates are not available from the financial data alone.
LXEO company profile · for informational purposes only — not investment advice.
Track LXEO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free